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Background
Although private companies have tested pesti-
cides on human subjects since the 1960s, the
public debate about the ethics of such experi-
ments began to simmer in 1998, when the
Environmental Working Group (EWG)
released a report titled The English Patients:
Human Experiments and Pesticide Policy
(1998). According to the report, the compa-
nies exposed volunteers to various insecticides
to determine safety levels for exposure to these
compounds. One of the experiments men-
tioned in the report involved the oral adminis-
tration of dichlorvos to 53 subjects. Another
experiment administered orange juice laced
with aldicard to 47 subjects (EWG 1998). The
media soon reported other pesticide experi-
ments conducted elsewhere. In one experiment
conducted by Novartis, managers for the
company ingested diazinon. Experiments con-
ducted by Novartis and Dow AgroSciences
each used 60 paid volunteers (Gorovitz and
Robertson 2000). In a study sponsored by
Dow AgroSciences, dozens of college-age
volunteers were paid $460 to swallow a pill
containing chlorpyrifos, a roach poison
(Shogren 2001).
The EWG report recommended that the
U.S. Environmental Protection Agency (EPA)
conduct a comprehensive review of its human
research policies and issue a moratorium on
the acceptance of data derived from privately
funded (or third party) human experiments. In
2000, the U.S. EPA announced that it would
not accept any pesticide data derived from pri-
vately funded toxicology research on human
subjects until the ethical and regulatory issues
were resolved (Lockwood 2004). In 2001,
the U.S. EPA asked the National Research
Council (NRC) to examine these issues; the
U.S. EPA issued an Advance Notice of
Proposed Rule-making in May 2003, before
the NRC had completed its report (U.S. EPA
2003). In the notice, the U.S. EPA requested
public comments on many different issues
concerning industry-funded human studies
submitted to the agency. The agency did not
unconditionally endorse applicability of
the Common Rule [Department of Health
and Human Services (DHHS) 2001] to those
studies, even though it has adopted the
Common Rule for U.S. EPA–sponsored
research (Silbergeld et al. 2004).
In February 2004, the NRC issued its
report. It recommended that privately funded
human dosing experiments for U.S. EPA regu-
latory purposes can be conducted only if they
meet strict scientiﬁc and ethical standards and
provide a public health or environmental bene-
fit. It also recommended that the Common
Rule should also apply to such research (NRC
2004). The NRC recommended that institu-
tional review boards (IRBs) should review all
proposed experiments to determine whether
they meet appropriate scientific and ethical
standards and that the U.S. EPA should estab-
lish a special review board to oversee these
types of experiments. The NRC also stated
that the U.S. EPA should not accept data
from previous experiments, which it said did
not meet scientific and ethical standards
(NRC 2004).
On 3 November 2004, the U.S. EPA
released a draft of a proposed plan for human
testing. In the proposed plan, the U.S. EPA
announced that it would evaluate data from
industry-sponsored studies on a case-by-case
basis “applying statutory requirements, the
Common Rule, and high ethical standards as
a guide, until such time as this practice is
replaced by a rulemaking” (U.S. EPA 2004a,
p. 6664). As soon as the U.S. EPA made this
announcement, some commentators faulted
the proposed plan for lack of consistency
and enforceability (Associated Press 2004).
However, the plan has helped clarify the U.S.
EPA’s position on human testing by signaling
its commitment to adhering to the Common
Rule for all human experiments. The U.S.
EPA plans to issue guidance for third-party
researchers for adherence to the Common
Rule and develop a ﬁnal rule by 2006.
A variety of laws, including the Federal
Food, Drug and Cosmetic Act (1999), the
Federal Insecticide, Fungicide and Rodenticide
Act (1964), and the Toxic Substances Control
Act (1999) grant the U.S. EPA authority to
regulate human exposures to environmental
toxins in the United States, including pesticide
residues on foods and in food additives. The
U.S. EPA establishes safety levels for exposure
to pesticides through a process known as pesti-
cide registration (U.S. EPA 2004b). Before a
manufacturer can sell a pesticide, it must regis-
ter it with the U.S. EPA. In registering a pesti-
cide, the U.S. EPA determines allowable
human exposures of the pesticide, based on
data submitted by pesticide manufacturers and
federal agencies, as well as its own research.
In arriving at an acceptable exposure, the
U.S. EPA considers exposures from different
sources, such as agricultural work and inges-
tion of food with traces of pesticides, as well as
cumulative exposures (NRC 2004). Users of
the pesticide, such as farmers and applicators,
are required to comply with the U.S. EPA’s
requirements for allowable human exposures.
The Food Quality Protection Act (FQPA),
which President Clinton signed in 1996,
amended existing laws pertaining to the U.S.
EPA. Before the FQPA, the U.S. EPA regu-
lated allowable pesticide exposure in food
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(NOAEL) in animal studies. After establishing
a NOAEL in animals (usually rodents), the
U.S. EPA would usually add a 10-fold inter-
species safety factor to allow for differences
between animals and humans, and a 10-fold
intraspecies safety factor to account for varia-
tion in sensitivities among humans. Thus, the
allowable exposure in human beings would
usually be no more than 1% of the NOAEL
exposure. The FQPA mandated an additional
10-fold increase in safety to account for varia-
tions between adults and children when there
are no data to support a smaller safety factor.
Therefore, under the FQPA, many chemicals
would have an allowable exposure of no more
than 0.1% of the NOAEL in animals. This
change in the allowable exposure would have a
signiﬁcant impact not only on pesticide com-
panies but also on agriculture, which depends
heavily on pesticides. In implementing the
law, the U.S. EPA has focused on 40 different
organophosphates, which have been used to
kill insects for many years.
Faced with higher safety standards for a
variety of chemicals, some pesticide companies
decided to conduct experiments on human
subjects to produce data that they hoped
would convince the U.S. EPA to lower the
interspecies safety factor. From 1996 to 2004,
the U.S. EPA received 20 studies from private
companies providing human dosing data on
pesticide toxicity (U.S. EPA 2004a). Thus, a
law that was intended to provide additional
safety protection for children had the unin-
tended effect of encouraging some companies
to test toxic compounds on human beings to
avoid the regulatory impact of the law.
In the public debate surrounding pesti-
cide testing on human subjects, two distinct
positions have crystallized (Robertson and
Gorovitz 2000). The first position, adopted
by the NRC and others (NRC 2004; Oleskey
et al. 2004), holds that pesticide testing on
human subjects can be conducted, but only
under the most stringent scientiﬁc and ethical
standards, such as favorable benefit–risk
ratios, informed consent, equitable subject
selection, risk minimization, valid study
design, and scientific necessity. The second
position, adopted by environmental and pub-
lic health interest groups, maintains that these
experiments should be prohibited (Children’s
Environmental Health Network 1999; EWG
1998; Sharav 2003).
In this commentary, we evaluate what we
consider to be the strongest argument for pro-
hibiting any testing of pesticides on human
subjects—namely, that the benefits of the
experiments are not significant enough to
justify the risks posed to healthy subjects.
We challenge this argument by exploring the
beneﬁts of pesticide testing for human health,
discussing the scientific necessity of some
experiments, and proposing ways to reduce
the risks to subjects. We are not commenting
on the studies that have been conducted. We
accept Lockwood’s (2004) analysis that at
least six of the human dosing studies submit-
ted to the U.S. EPA were scientifically and
ethically ﬂawed. We are concerned here with
the broader question of whether any type of
experiment that intentionally exposes human
subjects to pesticides can meet scientiﬁc and
ethical standards.
Beneﬁts versus Risks in
Research
One of the most important principles of
ethical research is that the risks to the subjects
must be justified by virtue of the benefits
to the subject and to society (Emanuel et al.
2000; Levine 1988; Nuremberg Code 1949;
World Medical Association 2000). The
Common Rule codiﬁes this principle: “Risks
to subjects are reasonable in relation to antici-
pated benefits, if any, to subjects, and the
importance of the knowledge that may reason-
ably be expected to result” [Common Rule
(DHHS 2001)]. If the beneﬁts of testing pes-
ticides on human subjects do not outweigh
the risks, then these experiments should not
be conducted.
To determine whether the benefits of an
experiment outweigh its risks, one must con-
sider both sides of the beneﬁt−risk ratio. In the
experiments we are considering here, the sub-
jects would be healthy individuals who would
not stand to beneﬁt medically or psychologi-
cally from participation. They may benefit
economically from participation, but most
agencies and commentators hold that it is not
ethically appropriate to consider a financial
incentive to participate in an experiment as a
potential beneﬁt in calculating the beneﬁt−risk
ratio [Food and Drug Administration (FDA)
1998; NIH 2004]. Because the subjects do not
stand to beneﬁt from the experiments, the ben-
eﬁts of these experiments hinge on their poten-
tial beneﬁts to society, which are based on the
value of the knowledge produced.
Social Value
The principle that human experiments should
have some redeeming social value has been an
essential principle in human experimentation
since the adoption of the Nuremberg Code
(1949). Opponents of the pesticide experi-
ments have argued that these experiments do
not have any significant benefits for society.
According to the EWG (1998, p. 13), “the
degree to which society as a whole benefits
from the use of speciﬁc pesticides, and pesti-
cides generally, is the subject of heated debate.
It is not obvious that these debatable social
beneﬁts alone would justify experimental risks
to humans.” Richard Wiles, vice president
for research for the EWG, also challenges
the social benefits of the research: “This is
not research designed to ﬁnd a cure for a dis-
ease or to generate a new scientific advance”
(Kamenetsky 2003, p. 1).
Even though the disputed experiments
would not be designed to diagnose, treat, or
prevent a disease, they could yield knowledge
about the toxic effects of pesticides on humans,
which could promote human health (NRC
2004). First, the knowledge obtained from the
experiments could be used by the U.S. EPA to
impose stricter safety standards on the chemi-
cals under investigation. In some situations, a
more than 10-fold interspecies safety factor
may be required to protect the general human
population or susceptible subpopulations
(Cranor 1997). For this outcome to happen, it
is important that the experiments have sufﬁ-
cient statistical power to demonstrate that a
greater (or less) than 10-fold interspecies safety
factor is needed for a particular chemical.
Because pesticide companies, like drug compa-
nies, would have a strong ﬁnancial motive for
not reporting unfavorable results, steps should
be taken to ensure that they do not suppress
such findings (Angell 2004). All data from
such studies submitted to the U.S. EPA should
be publicly available within a reasonable time
after completion of the studies.
Second, knowledge about how pesticides
affect human beings can be useful in address-
ing human health issues outside of the U.S.
EPA’s regulatory authority. People are exposed
to pesticides in variety of different contexts,
such as exposure from vehicles and clothing;
exposure in public places that use pesticides;
and exposure in the air, soil, and water.
Knowledge about how pesticides affect
human beings could be useful in taking meas-
ures to reduce pesticide exposure in areas that
lie beyond the U.S. EPA’s domain and could
encourage Congress to adopt new legislation
to protect the public from pesticides.
Third, the proposed experiments may
contribute to our understanding of the useful-
ness of animal models in toxicology testing
because they would allow researchers to com-
pare human and animal data. In toxicology
research, scientists draw conclusions about
the impacts of chemical on human health
based on experiments in animals. For example,
chemicals may be classified as carcinogens
if they cause cancer in laboratory animals.
Although animal models play an essential role
in all toxicology testing, they do have some
limitations due to differences in genetics,
anatomy, and physiology between humans and
different animal species (Brent 2004; Swanson
et al. 2004). Understanding limitations of ani-
mal models may contribute to human health
by improving our knowledge of the toxic
effects of chemicals in human beings and con-
tributing to effective regulation of pesticides,
pharmaceuticals, and other compounds.
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there are some potential beneﬁts from testing
pesticides on human subjects, yet still main-
tain that the benefits are not great enough.
One might argue that the benefits must be
at least as great as the potential benefits of
research that exposes healthy subjects to an
equivalent amount of risk, such as Phase I
clinical trials of new pharmaceuticals. We
address this objection more fully below, when
we evaluate the risks of human pesticide test-
ing. At this juncture, however, we would like
to point out that new drugs are not always
beneﬁcial, and that some cause a greater deal
of harm, as demonstrated by Merck’s decision
to withdraw Vioxx from the market (Miller
2005). In deciding whether to approve a new
drug, the Food and Drug Administration
weighs benefits and risks of the drug. If the
risks are high, then the beneﬁts must also be
high. If the risks are low, then the beneﬁts do
not have to be as high. We argue below that
the risks of some types of pesticide experi-
ments, if implemented and monitored prop-
erly, can be low enough to justify the use of
human subjects.
Scientiﬁc Necessity
If the knowledge produced by pesticide exper-
iments has some social value, the benefits of
the experiments will not outweigh the risks if
the knowledge can be obtained by other
means. One of the key principles of research
ethics is that human beings should not be
used in experiments if those experiments are
not scientifically necessary (Emanuel et al.
2000; Nuremberg Code 1949). If an experi-
ment is not scientifically necessary, then the
risks of the experiment outweigh the beneﬁts
of the experiment (Levine 1988). Critics of
pesticide testing on human subjects hold that
there is no need to conduct these experiments
because scientists can obtain adequate data
from experiments on animals, as well as stud-
ies on human beings that do not involve con-
trolled experiments, such as epidemiologic or
ﬁeld studies (EWG 1998).
Without a doubt, epidemiologic studies
and ﬁeld studies can provide useful informa-
tion about the effects of pesticides on human
health. For example, an epidemiologic study
by Kato et al. (2004) examined 376 cases and
463 controls from a cancer registry to deter-
mine whether pesticide exposure increases the
risk of non-Hodgkin lymphoma (NHL) in
women. The study found that women who
worked on a farm where pesticides were used
for at least 10 years had twice the risk of
NHL in relation to a comparable group of
women who did have this pesticide exposure.
A similar epidemiologic study conducted by
McDuffie et al. (2001) examined 517 cases
and 1,506 controls of Canadian men from a
variety of occupations. The study concluded
that NHL is associated with several different
pesticides. A ﬁeld study conducted by Aprea
et al. (1997) measured pesticides in the urine
of agricultural workers 1, 5, and 11 days after
exposure to pesticides during vine spraying
and leaf thinning. The study compared the
agricultural workers to a control group of
46 people who did not have the same expo-
sure. Aprea et al. (1997) found that pesticide
excretion was positively correlated with pesti-
cide exposure, with the peak pesticide excre-
tion the night after exposure. Coronado et al.
(2004) performed a similar type of study,
using a random sample of agricultural work-
ers and their children. They measured pesti-
cide residues and pesticide excretion in urine.
Although these studies and others like them
provide scientists, clinicians, public health prac-
titioners, and regulators with important knowl-
edge, they have some limitations. First, they
have many different uncontrolled variables that
can confound data analysis and interpretation.
In all of these studies, subjects were exposed to
more than one type of pesticide as well as to
many other types of potentially toxic chemicals.
Exposures also were not uniform. The sub-
jects had variations in diet, tobacco use, envi-
ronmental temperature, water intake, alcohol
use, and other factors that can affect health.
Although epidemiologic and ﬁeld studies can
establish patterns and correlations, they can-
not adequately prove causation. Kato et al.
(2004) were careful to point out that their
study showed the pesticides increase the risk
of NHL but do not cause the disease. The
randomized, controlled clinical trial is the
gold standard for proving causation in clinical
research (Sackett et al. 1997). Controlled tri-
als also offer the best data concerning the
effects of pesticides in humans.
Second, to conduct epidemiologic or ﬁeld
studies of pesticides, the products must already
be on the market because one cannot measure
natural exposures to a chemical that people are
not using. Thus, epidemiologic and ﬁeld stud-
ies do not provide regulators or clinicians with
any information about a pesticide before its
introduction. It would often be important to
have better information about a pesticide
before human populations are exposed to that
pesticide, because this information could help
promote human health and safety. Although
the U.S. EPA examines animal data before
making decisions about new compounds, the
agency could also beneﬁt from having access
to human data.
The NRC (2004) recommended that three
types of experiments on human beings could
provide information not obtainable by other
methods or means: a) pharmacokinetic (PK)
studies, which are designed to elucidate how
pesticides are absorbed, metabolized, and elim-
inated by the human body; b) pharmaco-
dynamic (PD) studies, which are designed to
elucidate how pesticides affect human physi-
ology via their action on biomarkers; and
c) studies that examine the psychological and
behavioral effects of pesticides, such as nausea,
dizziness, fatigue, or headache. According to
the NRC (2004), the ﬁrst two types of studies
could be conducted at very low doses that
would pose very low risks to subjects. The
third type of study poses risks to human sub-
jects, which can be minimized through proper
population selection and protocol design,
according to the NRC (2004).
We disagree somewhat with the NRC on
these issues. For all these types of studies, it is
possible to develop ﬁeld studies, like the one
conducted by Aprea et al. (1997), that are eth-
ically less troubling than an intentional dosing
study. One can take advantage of the fact that
people expose themselves to pesticides to
design experiments that measure the effects of
pesticides on human beings. For example,
carefully assessing blood concentrations before
ﬁeld entry by agricultural workers, followed by
multiple time-point blood concentrations on
leaving the ﬁeld, could be used to determine
overall absorption and elimination kinetics.
Matching data from this type of study with
PD measurements could eliminate the need
for a clinical study that intentionally exposes
individuals to pesticides. Although this type of
study has many of the methodologic difﬁcul-
ties associated with classical epidemiology
studies, such as confounding variables and
bias, and some additional medical concerns,
such as conducting the research in the field
rather than in a clinical setting, it creates less
of an ethical problem than an intentional dos-
ing study because the subjects are already
exposed to pesticides in their daily lives. These
studies would pose few additional risks to sub-
jects beyond those that they would already
face in their environment.
Using ﬁeld studies to obtain pesticide data
has an important limitation, however: They
do not provide information about pesticides
that are not being used at all or that are not
being used frequently enough to obtain reli-
able data. For the method to work, one must
be able to recruit enough subjects to obtain
reliable and statistically signiﬁcant data. If one
wants to obtain human data on a pesticide
that is not being used at all or that is being
used infrequently, one must intentionally
expose human subjects to the chemical. Thus,
we believe there are good reasons to conduct
studies on pesticides that have not been intro-
duced to the market or are not being used fre-
quently enough to obtain reliable data from
field studies. Only these types of intentional
dosing studies are scientiﬁcally necessary.
Risk and Safety
If the experiments have social value and are
scientifically necessary, they will still not be
Pesticide testing on human subjects
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a favorable benefit−risk ratio. The benefits
of the experiments, though significant, are
probably not as high as the beneﬁts of a clini-
cal study on a new medical therapy. Could
the risks be kept low enough that the beneﬁts
would outweigh them? To address this ques-
tion, it is important to understand the dosing
regimen of the studies and compare it to
the dosing regimen used in Phase I trials on
healthy subjects. We realize that the compari-
son to Phase I drug trials is not completely
apt, because pesticides will not be used to
diagnose, treat, or prevent human diseases.
However, we make the comparison as a way
of understanding aspects of the studies related
to toxic chemical exposures.
A Phase I study occurs after extensive ani-
mal testing to determine whether the drug is
safe enough to test on human subjects. The
goal of a Phase I trial of a new drug is to deter-
mine its safety for human use. Phase I studies
usually are conducted on healthy volunteers,
although some Phase I studies are conducted
on very ill subjects, such as patients with
advanced cancer. Phase I studies follow a dose-
escalation regimen designed to determine the
maximum tolerable dose (MTD). The MTD
for a particular subject is the dose at which the
drug causes toxicity or at which the subject
experiences intolerable symptoms, such as
nausea, pain, or difﬁculty breathing. The pes-
ticide experiments that we have been dis-
cussing would be designed not to measure
the MTD for a chemical, but to measure the
NOAEL (i.e., the level of exposure to the
chemical at which the subject has no observ-
able adverse effects). To measure the NOAEL,
the experiments escalate the exposure level
until some predeﬁned effect is observed, such
as an effect on a biomarker, speciﬁc levels of
the chemical in the subject’s blood or urine,
or symptoms such as nausea, dizziness, or
headache. The adverse effects could be meas-
ured by giving the subjects very low exposures
and then stopping the escalation as soon an
adverse effect is observed.
Would these types of experiments be safe
enough? The NRC (2004) concluded that
studies to measure NOAELs for pesticides
would probably be at least as safe as studies
designed to measure MTDs for drugs. One
might argue that short-term risks of exposing
people to low levels of pesticide would be
lower than the risks of exposing people
to toxic levels of drugs, since an observable
adverse effect is safer than toxicity. But what
about the long-term effects of pesticide exper-
iments? Unfortunately, we are not aware of
any data on the long-term risks of intention-
ally exposing human subjects to low doses
of pesticides for a short period of time.
However, data from other types of studies
indicate that there could be some signiﬁcant
long-term risks of limited exposures to pes-
ticides because pesticides can induce muta-
tions that cause cancer and may have adverse
impacts on the neuromuscular, cardiovascu-
lar, and endocrine systems (NRC 2004). To
minimize long-term risks from intentionally
exposing human subjects to pesticides, we
recommend that human subjects should not
be exposed to pesticides that are known car-
cinogens or that are known to cause perma-
nent damage to human tissues or organs in
low doses.
We agree with the NRC (2004) that pes-
ticide experiments on human subjects should
not be conducted if the pesticides are
expected to cause serious or irreversible harm
to human subjects. The experiments can be
conducted only if the harms they are expected
to produce are not serious and are reversible.
For example, the presence of a pesticide in the
blood or urine is an effect that is not serious
and is reversible because the body will con-
tinue to eliminate the pesticide. Tissue or
organ damage, however, might be serious or
irreversible. We also think that the burden of
proof should be on the researchers to prove
that a proposed study is not expected to pro-
duce effects that are serious or irreversible.
IRBs should assume that intentionally expos-
ing human subjects to even small doses of
pesticides may produce serious or irreversible
effects, unless the researchers produce evi-
dence to the contrary.
To minimize all of the risks from the
experiments discussed herein, we recommend
the following safety measures, most of which
have also been endorsed by the NRC (2004):
1. The experiments should take place in a clini-
cal setting, supervised by medical personnel.
2. Subjects should be carefully selected and
monitored.
3. The studies should exclude subjects who
are pregnant, are unhealthy, or have signiﬁ-
cant pesticide exposures in their daily lives.
4. Extensive animal testing should take place
to determine exposure levels that are not
likely to cause any serious or permanent
damage to subjects.
5. Escalation of exposure levels should proceed
cautiously and stop as soon as a well-
deﬁned, observable adverse effect is detected
or as soon as the expected maximum human
exposure in food, water, or the environment
is achieved.
6. Independent data and safety monitoring
boards (DSMBs) should be established to
monitor risks to subjects and protect them
from harm.
7. Researchers should have a clear definition
of an “adverse event” and immediately
report adverse events to the IRB, the DSMB,
research sponsors, and the U.S. EPA.
8. Subjects should be fully informed of the
risks of participation.
Conclusion
The strongest argument against any pesticide
testing on human subjects is that the beneﬁts
of the research do not outweigh the risks. [In
our supplemental material (http://ehp.niehs.
nih.gov/members/2005/7720/suppl.pdf), we
evaluate three other arguments against testing
pesticides on human subjects.] In this article,
we have attempted to rebut this argument by
showing that in some types of studies, the
beneﬁts would outweigh the risks. Such stud-
ies must meet at least four stringent conditions
[the supplemental material (http://ehp.niehs.
nih.gov/members/2005/7720/suppl.pdf) con-
tains a more complete list]:
1.The knowledge gained from the study is
expected to promote human health.
2.The knowledge cannot be reasonably
obtained by other means.
3. The study is not expected to cause serious
or irreversible harm to the subjects.
4. Appropriate safeguards are in place to mini-
mize harm to the subjects.
Because we think that some of the experi-
ments discussed in this article could meet
these conditions, we do not support a ban on
experiments that intentionally expose human
subjects to pesticides, and we support the
U.S. EPA’s decision to move forward with
rule making and guidance in this area.
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